# US 2022/0023432 A1 · Bicyclic peptide ligands specific for mt1-mmp

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023432 A1
- Document ID: US20220023432A1
- Status: Published application
- Kind: A1
- Application number: 17/443,222
- Filed: 2021-07-22
- Published: 2022-01-27
- Earliest claimed: 2014-10-29
- Assignees: BicycleRD Limited
- Applicants: BicycleRD Limited
- Inventors: Daniel Paul TEUFEL; Catherine Lucy Stace; Silvia Pavan; Edward Walker; Leonardo Baldassarre
- Web page: https://patentgrep.com/patent/US20220023432A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/195: having an amino group
- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.

## Claims

### Claim at position 1

1-41. (canceled)

### Claim 42

A compound which is selected from:
wherein Bicycle represents a peptide ligand specific for MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold, which is TBMB (1,3,5-tris(bromomethyl)benzene), and which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, and wherein the peptide ligand comprises an amino acid sequence of:
(SEQ ID NO: 5)
(β-Ala)-Sar10-AC(D-A1a)NE(1Na1)(D-A1a)CEDFYD
(tBuGly)C,
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The compound according to claim 42 which is:
or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 42)

The compound according to claim 42 which is:
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 42)

The compound according to claim 42 which is:
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 42)

The compound according to claim 42 which is:
or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 42)

The compound according to claim 42, wherein the pharmaceutically acceptable salt is selected from the sodium, potassium, calcium, or ammonium salt.

### Claim 48 (depends on 42)

A pharmaceutical composition which comprises the compound of claim 42, in combination with one or more pharmaceutically acceptable excipients.

### Claim 49 (depends on 42)

A method of treating cancer in a patient comprising administering to the patient the compound of claim 42, or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the cancer is selected from the group consisting of a tumor of epithelial origin, a tumor of the central or peripheral nervous system, and a fibrosarcoma.

### Claim 51

A compound which is:
or a pharmaceutically acceptable salt thereof, wherein Bicycle represents a peptide ligand specific for MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold, which is TBMB (1,3,5-tris(bromomethyl)benzene), and which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, and wherein the peptide ligand comprises an amino acid sequence of:
(SEQ ID NO: 5)
(β-Ala)-Sar10-AC(D-A1a)NE(1Na1)(D-A1a)CEDFYD
(tBuGly)C.

### Claim 52 (depends on 51)

The compound according to claim 51, wherein the pharmaceutically acceptable salt is selected from the sodium, potassium, calcium, or ammonium salt.

### Claim 53 (depends on 51)

A pharmaceutical composition which comprises the compound of claim 51, in combination with one or more pharmaceutically acceptable excipients.

### Claim 54 (depends on 51)

A method of treating cancer in a patient comprising administering to the patient the compound of claim 51, or a pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 54)

The method of claim 54, wherein the cancer is selected from the group consisting of a tumor of epithelial origin, a tumor of the central or peripheral nervous system, and a fibrosarcoma.

### Claim 56 (depends on 55)

The method of claim 55, wherein the tumor of epithelial origin is selected from the group consisting of a carcinoma of the bladder and urinary tract, breast, gastrointestinal tract, liver, gall bladder and biliary system, exocrine pancreas, kidney, lung, head and neck, ovary, fallopian tubes, peritoneum, vagina, vulva, penis, cervix, myometrium, endometrium, thyroid, adrenal, prostate, skin and adnexae.

### Claim 57 (depends on 56)

The method of claim 56, wherein the carcinoma of the lung is selected from the group consisting of an adenocarcinoma, a small cell lung carcinoma, a non-small cell lung carcinoma, a bronchioalveolar carcinoma and a mesothelioma.

### Claim 58 (depends on 56)

The method of claim 56, wherein the carcinoma of the lung is a non-small cell lung carcinoma.

### Claim 59 (depends on 55)

The method of claim 55, wherein the cancer is a tumor of the central or peripheral nervous system.

### Claim 60 (depends on 55)

The method of claim 55, wherein the cancer is a fibrosarcoma.
